AbbVie has signed a deal with Teneobio to develop a B-cell maturation antigen (BCMA)-targeting bispecific antibody for multiple myeloma.
News
Study says ‘Older people need better access to psychological therapies’
A new study has found that 10% of adults aged over 75 have major depressive disorder, and over one third sub-threshold depressive symptoms.
SAW receives £1.5M funding for point-of-care diagnostics technology
SAW Diagnostics has announced that Innovate UK has awarded the company a £1.5 million grant in support of its low-cost sample preparation system, for use in infectious disease detection and other applications.
Gilead’s selonsertib fails in PhIII NASH trial
Gilead’s selonsertib has failed to hit a key target in a late-stage study involving patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH).
Yescarta rejected among other SMC decisions
Gilead’s CAR-T therapy Yescarta has been rejected by the Scottish Medicines Consortium (SMC) for use on NHS Scotland, but Novartis’ Kymriah was given a green light.
Takeda’s Adcetris gets EU green light
Takeda has announced that the European Commission has extended the current marketing authorisation of Adcetris to include treatment of adults with previously untreated CD30+ Stage IV Hodgkin lymphoma.
New ‘Trojan horse’ cancer treatment shows early promise
A brand new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.
Professor Dame Sally Davies to step down as chief medical officer
Professor Dame Sally Davies will leave her post as chief medical officer for England and chief medical officer advisor to the UK government later this year to take up a new role.
ABPI warns of greater exposure to fake meds under no-deal Brexit
The Association of the British Pharmaceutical Industry (ABPI) has expressed fears that the UK will drop out of the “safest medicines system in the world” in the event of no-deal Brexit.
UniQure’s gene therapy AMT-061 looking promising mid trial
UniQure’s experimental gene therapy has shown sustained Factor IX activity in a Phase II study assessing its potential to treat haemophilia B.
Grey Wolf completes £10m funding for immuno-oncology therapies
Grey Wolf Therapeutics has completed a £10 million series A financing to fund development of immuno-oncology therapies to increase tumour visibility.
European measles cases hit a ten year high
Cases of measles in Europe are at the highest rate in a decade, due to a growing number of pockets where parents are refusing vaccination for their children, also known as ‘anti-vaxxers’.
NHS to operate lung cancer scanning trucks across UK
The NHS has announced plans to rollout lung cancer scanning trucks across the country, operating from supermarket car parks and aiming to save lives by catching the condition early.
NHS roll out digital checks for dementia and falls
Older patients may be spared dementia and falls by a new NHS tech roll-out, via digital checks that aim to save lives through diagnosis of sepsis, and other tools being made available in hospitals across the country as part of the NHS Long Term Plan.
Duchenne study causes Solid Biosciences’ shares to fall
Solid Biosciences’ shares have taken a hit after early results from a study of SGT-001 microdystrophin gene transfer for the treatment of Duchenne muscular dystrophy (DMD) fell short.
